Skip to main content
Erschienen in: Arthritis Research & Therapy 3/2011

01.12.2011 | Editorial

IL-17 in spondyloarthritis: is the T-party over?

verfasst von: Nataliya Yeremenko, Dominique Baeten

Erschienen in: Arthritis Research & Therapy | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The past decade has witnessed significant progress in revealing an important role for IL-17 in the pathogenesis of several immune-mediated inflammatory diseases. Recent studies have provided new insights into the cellular source of IL-17, originally identified as the signature cytokine of a distinct CD4+ T-cell subset known as Th17. Accumulating evidence suggests that the majority of the IL-17 released in inflammatory arthritis is produced by innate immune cells rather than T cells. Understanding molecular mechanisms behind these early innate immune responses will be the key to designing rational therapies targeting these important inflammatory pathways.
Literatur
1.
Zurück zum Zitat Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J: Analysis of interleukin-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17 mediated adaptive immune response. Arthritis Res Ther. 2011, 13: R95-10.1186/ar3370.PubMedCentralCrossRefPubMed Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J: Analysis of interleukin-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17 mediated adaptive immune response. Arthritis Res Ther. 2011, 13: R95-10.1186/ar3370.PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Di Meglio P, Di Cesare A, Laggner U, Chu CC, Napolitano L, Villanova F, Tosi I, Capon F, Trembath RC, Peris K, Nestle FO: The IL-23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One. 2011, 6: e17160-10.1371/journal.pone.0017160.PubMedCentralCrossRefPubMed Di Meglio P, Di Cesare A, Laggner U, Chu CC, Napolitano L, Villanova F, Tosi I, Capon F, Trembath RC, Peris K, Nestle FO: The IL-23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One. 2011, 6: e17160-10.1371/journal.pone.0017160.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Sarin R, Wu X, Abraham C: Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci USA. 2011, 108: 9560-9565. 10.1073/pnas.1017854108.PubMedCentralCrossRefPubMed Sarin R, Wu X, Abraham C: Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci USA. 2011, 108: 9560-9565. 10.1073/pnas.1017854108.PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA: HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009, 60: 2633-2643. 10.1002/art.24763.PubMedCentralCrossRefPubMed DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA: HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009, 60: 2633-2643. 10.1002/art.24763.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Baeten D, Sieper J, Emery P, Braun J, van der Heijde D, McInnes I, van Laar J, Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Bertolino A, Wright A, Hueber W: The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum. 2010, 62: 2840-2841. Baeten D, Sieper J, Emery P, Braun J, van der Heijde D, McInnes I, van Laar J, Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Bertolino A, Wright A, Hueber W: The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum. 2010, 62: 2840-2841.
6.
Zurück zum Zitat Bowness P, Ridley A, Shaw J, Chan AT, Wong-Baeza I, Fleming M, Cummings F, McMichael A, Kollnberger S: Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011, 186: 2672-2680. 10.4049/jimmunol.1002653.PubMedCentralCrossRefPubMed Bowness P, Ridley A, Shaw J, Chan AT, Wong-Baeza I, Fleming M, Cummings F, McMichael A, Kollnberger S: Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011, 186: 2672-2680. 10.4049/jimmunol.1002653.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, Robinson N, Buonocore S, Tlaskalova-Hogenova H, Cua DJ, Powrie F: Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006, 25: 309-318. 10.1016/j.immuni.2006.05.017.CrossRefPubMed Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, Robinson N, Buonocore S, Tlaskalova-Hogenova H, Cua DJ, Powrie F: Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006, 25: 309-318. 10.1016/j.immuni.2006.05.017.CrossRefPubMed
8.
Zurück zum Zitat Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB: Mast cell express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010, 184: 3336-3340. 10.4049/jimmunol.0903566.CrossRefPubMed Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB: Mast cell express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010, 184: 3336-3340. 10.4049/jimmunol.0903566.CrossRefPubMed
9.
Zurück zum Zitat Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT: Mast cell and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011, Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT: Mast cell and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011,
10.
Zurück zum Zitat Geremia A, Arancibia-Cárcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, Travis SP, Powrie F: IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011, 208: 1127-1133. 10.1084/jem.20101712.PubMedCentralCrossRefPubMed Geremia A, Arancibia-Cárcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, Travis SP, Powrie F: IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011, 208: 1127-1133. 10.1084/jem.20101712.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Eklund KK, Remitz A, Kautiainen H, Reitamo S, Leirisalo-Repo M: Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients. Rheumatology. 2006, 45: 1573-1575.CrossRefPubMed Eklund KK, Remitz A, Kautiainen H, Reitamo S, Leirisalo-Repo M: Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients. Rheumatology. 2006, 45: 1573-1575.CrossRefPubMed
Metadaten
Titel
IL-17 in spondyloarthritis: is the T-party over?
verfasst von
Nataliya Yeremenko
Dominique Baeten
Publikationsdatum
01.12.2011
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 3/2011
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3351

Weitere Artikel der Ausgabe 3/2011

Arthritis Research & Therapy 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.